# Phase 2 behavior trials recruiting: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials in phase 2 for behavior that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 behavior trials: 27 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/behavior

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 22, 2026 | NCT07602699 | Multi-Site Trial of Tirzepatide for Smoking Cessation | University of Southern California | Phase 2 | Recruiting | Smoking Cessation, Smoking Behaviors | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602699) |
| April 3, 2026 | NCT07509112 | Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study | Kirby Institute | Phase 2 | Not yet recruiting | Methamphetamine Use Disorder | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509112) |
| January 9, 2026 | NCT07328529 | Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome | Azevan Pharmaceuticals | Phase 2 | Not yet recruiting | Aggressive Behavior in Fragile X Syndome | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328529) |
| December 18, 2025 | NCT07292883 | Accelerated dTMS Smoking Cessation | Waypoint Centre for Mental Health Care | Phase 2 | Recruiting | Tobacco Use Disorder, Addiction Nicotine | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292883) |
| November 25, 2025 | NCT07249554 | Combination Therapy for Alcohol Use Disorder | Johns Hopkins University | Phase 2 | Not yet recruiting | Alcohol Use Disorder | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249554) |
| July 30, 2025 | NCT07094503 | Adolescent Chatbot | Washington University School of Medicine | Phase 2 | Recruiting | Body Image Disturbance, Disordered Eating Behaviors, Eating Disorder Prevention | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07094503) |
| July 29, 2025 | NCT07091279 | Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism | Sponsor not shown (see the record) | Phase 2 | Recruiting | Autism Spectrum Disorder, Challenging Behaviour, Aggression, Severe Disruptive Behaviour Disorders, Self-injury | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07091279) |
| July 24, 2025 | NCT07083635 | Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users | Chulalongkorn University | Phase 2 | Recruiting | Menstruation Disturbances, Metrorrhagia, Uterine Hemorrhage, Contraception Behavior | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07083635) |
| May 29, 2025 | NCT06994338 | Tirzepatide for Alcohol Use Disorder | University of Southern California | Phase 2 | Recruiting | Alcohol Use Disorder, Obesity and Overweight, Alcohol | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06994338) |
| February 5, 2025 | NCT06809153 | Putting Children First - Parent Training for Parents in High Conflict | IRIS Media Inc | Phase 2 | Not yet recruiting | Parenting Behavior, Parent Management Training, Parent-Child Relations, Child Behavior | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06809153) |
| January 23, 2025 | NCT06788587 | Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 | Recruiting | Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance Abuse, Methamphetamine Use Disorder | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06788587) |
| January 17, 2025 | NCT06781333 | Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. | Sponsor not shown (see the record) | Phase 2 | Recruiting | Alzheimer Disease, Agitation in Dementia | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06781333) |
| November 29, 2024 | NCT06710431 | A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder | Afasci Inc | Phase 2 | Not yet recruiting | Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold, Depression Disorders, Sleep Disorder | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06710431) |
| October 2, 2024 | NCT06623669 | A Mobile Intervention to Reduce Pain and Improve Health-III | Wake Forest University | Phase 2 | Recruiting | Chronic Pain, Osteoarthritis, Obesity and Overweight, Inactivity | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06623669) |
| October 2, 2024 | NCT06622239 | Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury | Seoul National University Hospital | Phase 2 | Not yet recruiting | Nonsuicidal Self-Injury | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06622239) |
| August 12, 2024 | NCT06548490 | GLP-1R Agonist Treatment for Opioid Use Disorder | Milton S. Hershey Medical Center | Phase 2 | Recruiting | Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548490) |
| July 1, 2024 | NCT06482515 | Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue | University of Maryland, Baltimore | Phase 2 | Recruiting | Neoplasms, Blood Cancer, Fatigue, Diet Habit, Survivorship, Fasting, Intermittent | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06482515) |
| March 29, 2024 | NCT06337708 | Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women | Arizona State University | Phase 2 | Recruiting | Physical Activity, Exercise, Heart Diseases, Diabetes Mellitus, Physical Inactivity | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06337708) |
| August 14, 2023 | NCT05985850 | Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy | BC Centre on Substance Use | Phase 2 | Recruiting | Opioid Use Disorder, Methadone, Cannabis, Fentanyl | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05985850) |
| July 12, 2023 | NCT05942716 | Serotonin Control of Impulsivity in Tourette Disorder | Hospices Civils de Lyon | Phase 2 | Recruiting | Tourette Disorder | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05942716) |
| May 11, 2023 | NCT05854667 | Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 | Recruiting | Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance, Addiction | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05854667) |
| May 25, 2022 | NCT05389930 | Cannabis' Impact on Alcohol Consumption | Brown University | Phase 2 | Recruiting | Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05389930) |
| April 20, 2022 | NCT05336201 | Cognitive Remediation Intervention to Prepare for Transition of Care | University of Alabama at Birmingham | Phase 2 | Recruiting | Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05336201) |
| March 31, 2022 | NCT05304065 | Safe Treatment for Emergency Presentation for Suicidal Ideation and Behavior in Youth | University of California, Los Angeles | Phase 2 | Recruiting | Suicide, Suicidal, Self-Harm | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05304065) |
| February 1, 2022 | NCT05219175 | MDMA for Co-occurring PTSD and OUD After Childbirth | University of New Mexico | Phase 2 | Recruiting | Stress Disorders, Post-Traumatic, Opioid Use Disorder | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05219175) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Southern California | 2 |
| Johns Hopkins University | 2 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 2 |
| Arizona State University | 1 |
| Afasci Inc | 1 |
| BC Centre on Substance Use | 1 |
| Brown University | 1 |
| University of New Mexico | 1 |
| Azevan Pharmaceuticals | 1 |
| Wake Forest University | 1 |
| Milton S. Hershey Medical Center | 1 |
| Washington University School of Medicine | 1 |
| University of Maryland, Baltimore | 1 |
| University of Alabama at Birmingham | 1 |
| Chulalongkorn University | 1 |
| Kirby Institute | 1 |
| Seoul National University Hospital | 1 |
| University of California, Los Angeles | 1 |
| Eastern Virginia Medical School | 1 |
| IRIS Media Inc | 1 |
| Hospices Civils de Lyon | 1 |
| Waypoint Centre for Mental Health Care | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 18 |
| Canada | 4 |
| Thailand | 1 |
| Australia | 1 |
| South Korea | 1 |
| France | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Rail services in the United States](https://specstream.ai/data/businesses/rail-services/united-states)
- [Dumpster rental companies in the United States](https://specstream.ai/data/businesses/dumpster-rental-companies/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
- [Tapas bars in the United States](https://specstream.ai/data/businesses/tapas-bars/united-states)
- [Gastroenterology practices in the United States](https://specstream.ai/data/businesses/gastroenterology-practices/united-states)
